A splice donor variant in SLAMF1 is associated with canine atopic dermatitis
The discovery represents the first compelling genetic variant associated with CAD to be validated in more than one breed of dog. The study identifies <i>SLAMF1</i> as a potential pharmaceutical target and the associated variant as a biomarker to enable dog breeders to make informed breeding decisions to reduce risk of CAD in future generations. The presence of the <i>SLAMF1</i> variant in many dog breeds and free-roaming dogs worldwide, indicates its potential role in contributing to the global risk of CAD.
Authors
- Jason T. Huff (ORCID: https://orcid.org/0000-0002-0088-1640)
- Rebecca Chodroff Foran (ORCID: https://orcid.org/0000-0001-7210-9329)
- Oliver P. Forman (ORCID: https://orcid.org/0000-0003-2817-2165)
- Michelle Daya (ORCID: https://orcid.org/0000-0002-9057-6593)
- Jamie Freyer (ORCID: https://orcid.org/0000-0002-0223-8747)
- Julia Labadie (ORCID: https://orcid.org/0000-0002-9942-7797)
- Janet E. Alexander (ORCID: https://orcid.org/0000-0002-1028-4022)
- Christian M. Leutenegger (ORCID: https://orcid.org/0000-0003-0345-3024)
- Debbie Gow (ORCID: https://orcid.org/0000-0002-7411-1673)
- M. Denyer (ORCID: https://orcid.org/0000-0001-9667-5683)
- Christian Savard (ORCID: https://orcid.org/0000-0003-0254-2228)
- A. G. Kerr
- Yaindrys Rodriguez Olivera
- Cecilia Lozoya
Institutions
- Carolina Veterinary Specialists (US)
- Visioncare Research (GB)
- Wisdom Health (United States) (US)
- CS Diagnostics (DE)
Publication Details
- Journal
- Frontiers in Veterinary Science
- Published
- 2025-06-19
- DOI
- https://doi.org/10.3389/fvets.2025.1550617
- Citations
- 1
- Primary Topic
- T-cell and B-cell Immunology
- Type
- article
- Field-Weighted Citation Impact
- 0.80